Drugs / FLOSEAL Hemostatic Matrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01410240 | Sep 2011 → Jan 2013 | osteoarthritis | Baxter Healthcare Corporation | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLOSEAL Hemostatic Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01410240 ↗ |
| Known as | FLOSEAL | “FLOSEAL” NCT01410240 ↗ |
| Route | Topical | “FLOSEAL will be applied topically to areas of the knee where bleeding is observed” NCT01410240 ↗ |